Oxford pauses dosing in trial of AstraZeneca COVID-19 vaccine in children, teenagers

Posted on

The University of Oxford has commissioned the AstraZeneca PLC to investigate the shooting in children and adolescents. The COVD-19 vaccine developed has been discontinued, leaving more information on the rare cases of hemorrhage in adults. The Wall Street Journal reported Tuesday.

A spokesman for Oxford told the Journal that the trial itself did not raise any safety issues, but widespread concerns about rare and rare problems in adults led to more regular reviews to investigate any possible link to the vaccine in the UK and Europe. Have started.

A senior European Medicines Agency (EMA) official said in an interview today that there was a link between the AstraZeneca CVID-19 vaccine and a rare blood clot in the brain, but the possible causes were not yet known.

However, the EMA said in a statement later that a review of the vaccine was ongoing and that it was expected to announce its results on Wednesday or Thursday. A spokeswoman for AstraZeneca declined to comment.

“In my opinion, we can now say that it is clear that the vaccine is associated with a blood clot in the brain. However, we still do not know the reason for this reaction, “Marco Cavalli, chairman of the vaccination team at the EMA, told Italy’s Daily Il Masseiro.

The cavalry did not provide any evidence to support his comments.

The EMA has repeatedly stated that the benefits outweigh the risks to AstraZeneca as it is the leading cause of cerebral palsy in 9.2 million people in the European Economic Area known as cerebral venous sinus thrombosis (CVST) Goes.

Leave a Reply

Your email address will not be published. Required fields are marked *